➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Harvard Business School
Baxter
Express Scripts
Merck

Last Updated: October 24, 2020

DrugPatentWatch Database Preview

Details for Patent: 6,346,532

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,346,532
Title: Amide derivatives or salts thereof
Abstract:##STR1## Amide derivatives represented by general formula (I) or salts thereof wherein each symbol has the following meaning: ring B: an optionally substituted heteroaryl optionally fused with a benzene ring; X: a bond, lower alkylene or lower alkenylene optionally substituted by hydroxy or lower alkyl, carbonyl, or a group represented by --NH-- (when X is lower alkylene optionally substituted by lower alkyl which may be bonded to the hydrogen atom bonded to a constituent carbon atom of ring B to form lower alkylene to thereby form a ring); A: a lower alkylene or a group represented by -(lower alkylene)--O--; R.sup.1a and R.sup.1b : the same or different and each hydrogen or lower alkyl; R.sup.2 : hydrogen or halogeno; and Z: nitrogen or a group represented by .dbd.CH--. The compounds are useful as a diabetes remedy which not only functions to both accelerate the secretion of insulin and enhance insulin sensitivity but has an antiobestic action and an antihyperlipemic action based on its selective stimulative action on a .beta..sub.3 receptor.
Inventor(s): Maruyama; Tatsuya (Tsukuba, JP), Suzuki; Takayuki (Tsukuba, JP), Onda; Kenichi (Tsukuba, JP), Hayakawa; Masahiko (Tsukuba, JP), Moritomo; Hiroyuki (Tsukuba, JP), Kimizuka; Tetsuya (Tsukuba, JP), Matsui; Tetsuo (Tsukuba, JP)
Assignee: Yamanouchi Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:09/529,096
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,346,532
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 6,346,532

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Apgdi MYRBETRIQ mirabegron TABLET, EXTENDED RELEASE;ORAL 202611-001 Jun 28, 2012 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Apgdi MYRBETRIQ mirabegron TABLET, EXTENDED RELEASE;ORAL 202611-002 Jun 28, 2012 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,346,532

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan9-285778Oct 17, 1997
PCT Information
PCT FiledOctober 15, 1998PCT Application Number:PCT/JP98/04671
PCT Publication Date:April 29, 1999PCT Publication Number: WO99/20607

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
McKinsey
Moodys
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.